Teva says gluten challenge study succeeds in celiac disease

Data ReadoutpositivePositive

AI Analysis

Summary

Teva Pharmaceuticals announced positive topline results from a gluten challenge study showing that a single injection of an experimental antibody significantly reduced intestinal damage in celiac disease patients who consumed gluten daily.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Single injection of experimental antibody significantly reduced intestinal damage in celiac disease patients who consumed gluten daily

Importance:6/10

Sentiment:

0.75

celiac diseaseantibodygluten challenge studyintestinal damagepositive trial data

Related Companies

$TEVA

Read the original article

Published by Endpoints News on September 2, 2026 2:58 PM

Read Original